Drug intelligence / Profile preview

Anatara Lifesciences anti-obesity program

Development stage: Preclinical
Lead developer: Anatara Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Anatara Lifesciences' anti-obesity program is a preclinical-stage development effort focused on creating an oral, small molecule agonist of the Glucagon-like peptide 1 (GLP-1) receptor. By targeting the GLP-1 pathway, the program aims to provide a more convenient oral alternative to the injectable peptide-based GLP-1 agonists currently used for appetite suppression and weight management. The program is designed to address the global need for effective and accessible obesity treatments by utilizing a small molecule modality that facilitates oral delivery and potentially improves patient compliance compared to subcutaneous injections.

Other names: Anti-Obesity ProgramAnatara GLP-1 program

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on Anatara Lifesciences anti-obesity program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anatara Lifesciences anti-obesity program.

Explore the full profile